SURVIVAL OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH SYSTEMIC SCLEROSIS


Cite item

Full Text

Abstract

Aim. To study survival of patients with a natural course of pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SS). Material and methods. Twenty SD patients with PAH and 71 SS patients free of PAH were followed up for 10 years (1998-2008) when therapy with specific pulmonary vasodilators was not available. Survival curves for both groups were plotted by Kaplan-Mayer method. Results. One-, 3and 5-year survival were 85, 25 and 5%, respectively, in the SS-PAH group and 99, 82 and 77% in the SS group, respectively. The differences were significant (р < 0,001). Survival median in the group SS-PAH was 32 months. Conclusion. The above evidence is comparable to the results obtained earlier and demonstrate a fatal outcome of the disease in the absence of therapy with specific pulmonary vasodilators.

About the authors

A V Volkov

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sandy@yahoo.com
канд. мед. наук, рук. лаб. функциональной и ультразвуковой диагностики НИИР РАМН

T V Martynyuk

Russian Cardiological Research Center

канд. мед. наук, ст. науч. сотр. отд. системных гипертензий

N N Yudkina

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

мл. науч. сотр

N M Danilov

Russian Cardiological Research Center

Email: ndanilov@yandex.ru
канд. мед. наук, ст. науч. сотр. отд. системных гипертензий

S I Glukhova

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sveglukhova@yandex.ru
науч. сотр

N G Guseva

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

д-р мед. наук, проф., вед. науч. сотр

I E Chazova

Russian Cardiological Research Center

Email: chazova@notmail.com
д-р мед. наук, проф., член-корр. РАМН, дир.

V A Nasonova

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

References

  1. Lee P., Langevitz P., Alderdice C. A. et al. Mortality in systemic sclerosis (scleroderma). Quart. J. Med. 1992; Suppl. 82: 139—148.
  2. Hesselstrand R., Scheja A., Aakesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann. Rheum. Dis. 1998; 57: 682—686.
  3. Steen V. D., Medsger T. A. Jr. Changes of causes of death in systemic sclerosis, 1972—2002. Ann. Rheum. Dis. 2007; 66: 940—944.
  4. Koh E. T., Lee P., Gladman D. D. et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol. 1996; 35: 989—993.
  5. Kawut S. M., Taichman D.B., ArcherChicko C.L. et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003. 123: 344—350.
  6. Stupi A. M., Steen V. D., Owens G. R. et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthr. and Rheum. 1986; 29: 515—524.
  7. Williams M. H., Das C., Handler C. E. et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92 (7): 926—932.
  8. Hoeper M. M., Markevych I., Spiekerkoetter E. et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 2005; 26: 858—863.
  9. Masi A. T., Medsger T. A. Jr., Altman R. D. et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthr. and Rheum. 1980; 23: 581—590.
  10. LeRoy E. C., Black C. M., Fleischmajer R. et al. Scleroderma: classification, subsets and pathogenesis. Br. J. Rheumatol. 1988; 15: 202—205.
  11. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galie N., Hoeper M. M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219—1263.
  12. Badesch D. B. Update on Pulmonary Hypertension 2008. ATS Annual Session 2008. G1—S13.
  13. Humber M. et al. Pulmonary Arterial Hypertesion in France: Results from a National Registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023—1030.
  14. Sunderketter C., Herrgott I., Bruckner C. et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br. J. Dermatol. 2009; 160: 835—843.
  15. Shah A. A., Wigley F. M., Hummers L. K. Teleangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J. Rheumatol. 2009; 37: 98—104.
  16. Morgan J. M., Griffiths M., de Bois R. M., Evans T. W. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991; 99: 551—556.
  17. Peters-Golden M., Wise R. A., Schneider P. et al. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984; 63: 221—231.
  18. Steen V. D., Graham G., Conte C. et al. Isolated diffusion capacity reduction in systemic sclerosis. Arthr. and Rheum. 1992; 35: 765—770.
  19. Matucci-Cerinic M., Steen V., Nash P., Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford) 2009; 48 (Suppl 3): iii8—iii13.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies